Table of Content

1 Market
1.1 Product Definition
1.2 Inclusion and Exclusion
1.3 Scope of the Study
1.4 Key Questions Answered in the Report

2 Research Methodology
2.1 Global Molecular Oncology Diagnostics Market: Research Methodology
2.2 Primary Data Sources
2.3 Secondary Data Sources
2.4 Market Estimation Model
2.5 Criteria for Company Profiling

3 Global Molecular Oncology Diagnostics Market: Overview
3.1 Market Overview
3.1.1 Evolution of Molecular Cancer Diagnostics and Current Status
3.2 Global Molecular Oncology Diagnostics Market Size and Forecast (2021-2032)
3.3 Global Incidence and Prevalence of Cancer (by Type)
3.3.1 North America
3.3.1.1 Solid Tumor
3.3.1.2 Hematological Malignancy
3.3.2 Europe
3.3.2.1 Solid Tumor
3.3.2.2 Hematological Malignancy
3.3.3 Asia-Pacific
3.3.3.1 Solid Tumor
3.3.3.2 Hematological Malignancy
3.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
3.4.1 Impact on Market Size
3.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
3.6 Laboratory Developed Test (LDT) Vs. In Vitro Diagnostic (IVD)
3.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market

4 Global Molecular Oncology Diagnostics Market: Industry Analysis
4.1 Legal Requirements and Framework in the U.S.
4.1.1 FDA Regulation
4.1.2 CMS Regulation (Reimbursement Scenario)
4.2 Legal Requirements and Framework in Europe
4.3 Legal Requirements and Framework in Asia-Pacific
4.3.1 China
4.3.2 Japan

5 Market Dynamics
5.1 Overview
5.1 Impact Analysis
5.2 Growth Drivers
5.2.1 Rising Incidence of Cancer Cases
5.2.2 Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem
5.2.3 Growth in Biomarker identification and Transformations in Molecular Techniques
5.3 Growth Restraints
5.3.1 Lack of Qualified Professionals
5.3.2 Opaque Regulatory Framework Delaying the Approval of New Molecular Diagnostic Tests
5.3.3 High Cost of Equipment Hindering the Adoption Rate
5.4 Growth Opportunities
5.4.1 Partnerships and Collaborations between Various Healthcare Stakeholders
5.4.2 Upsurge of Next-Generation Ultrasensitive Molecular Diagnostics

6 Competitive Landscape
6.1 Mergers and Acquisitions
6.2 Synergistic Activities
6.3 Product Launch and Approval Activities
6.4 Expansion, Insurance, and Other Key Developments
6.5 Market-Share Analysis
6.6 Growth-Share Analysis

7 Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021-2032
7.1 Overview
7.2 Kits and Assays
7.3 Instruments
7.4 Software

8 Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021-2032
8.1 Overview
8.2 Polymerase Chain Reaction (PCR)
8.3 Next-Generation Sequencing (NGS)
8.4 Immunohistochemistry (IHC)
8.5 Fluorescence In-Situ Hybridization (FISH)
8.6 Flow Cytometry
8.7 Other Technologies

9 Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021-2032
9.1 Overview
9.2 Clinical Diagnostic
9.3 Research Use

10 Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
10.1 Overview
10.1.1 Solid Tumor
10.1.1.1 Breast Cancer
10.1.1.2 Lung Cancer
10.1.1.3 Colorectal Cancer
10.1.1.4 Prostate Cancer
10.1.1.5 Ovarian Cancer
10.1.1.6 Other Solid Tumors
10.1.2 Hematological Malignancy
10.1.2.1 Lymphoma
10.1.2.2 Leukemia
10.1.2.3 Multiple Myeloma
10.1.2.4 Other Hematological Malignancies

11 Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021-2032
11.1 Overview
11.2 Hospitals and Diagnostic Centers
11.3 Reference Laboratories
11.4 Pharmaceutical and Biotechnology Companies
11.5 Academic and Research Institutes

12 Region
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Italy
12.3.5 Spain
12.3.6 Rest-of-Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 India
12.4.3 Japan
12.4.4 South Korea
12.4.5 Australia
12.4.6 Rest-of-Asia-Pacific
12.5 Rest-of-the-World (RoW)

13 Company Profiles
13.1 Agilent Technologies, Inc.
13.1.1 Company Overview
13.1.2 Role of Agilent Technologies, Inc. in the Global Molecular Oncology Diagnostics Market
13.1.3 Key Competitors of the Company
13.1.4 Business Strategies
13.1.4.1 Merger and Acquisition
13.1.4.2 Product Launch/Approval
13.1.4.3 Expansion
13.1.5 Financials
13.1.6 Analyst Perspective
13.2 Abbott.
13.2.1 Company Overview
13.2.2 Role of Abbott. in the Global Molecular Oncology Diagnostics Market
13.2.3 Key Competitors of the Company
13.2.4 Key Customers of the Company
13.2.5 Financials
13.2.6 Key Insights about the Financial Health of the Company
13.2.7 Analyst Perspective
13.3 Biocartis NV
13.3.1 Company Overview
13.3.2 Role of Biocartis NV in the Global Molecular Oncology Diagnostics Market
13.3.3 Key Competitors of the Company
13.3.4 Corporate Strategies
13.3.4.1 Synergistic Activities
13.3.5 Business Strategies
13.3.5.1 Product Launch/Approval
13.3.6 Financials
13.3.7 Analyst Perspective
13.4 Bio-Rad Laboratories, Inc.
13.4.1 Company Overview
13.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Molecular Oncology Diagnostics Market
13.4.3 Key Competitors of the Company
13.4.4 Corporate Strategies
13.4.4.1 Synergistic Activities
13.4.5 Business Strategies
13.4.5.1 Merger and Acquisition
13.4.5.2 Product Launch/Approval
13.4.6 Financials
13.4.7 Analyst Perspective
13.5 F. Hoffmann-La Roche Ltd.
13.5.1 Company Overview
13.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Molecular Oncology Diagnostics Market
13.5.3 Key Competitors of the Company
13.5.4 Corporate Strategies
13.5.4.1 Synergistic Activities
13.5.5 Business Strategies
13.5.5.1 Product Launch/Approval
13.5.5.2 Expansion
13.5.6 Financials
13.5.7 Analyst Perspective
13.6 QIAGEN N.V.
13.6.1 Company Overview
13.6.2 Role of QIAGEN N.V. in the Global Molecular Oncology Diagnostics Market
13.6.3 Key Competitors of the Company
13.6.4 Key Customers of the Company
13.6.5 Corporate Strategies
13.6.5.1 Synergistic Activities
13.6.6 Business Strategies
13.6.6.1 Merger and Acquisition
13.6.6.2 Product Launch/Approval
13.6.7 Financials
13.6.8 Analyst Perspective
13.7 Thermo Fisher Scientific, Inc.
13.7.1 Company Overview
13.7.2 Role of Thermo Fisher Scientific, Inc. in the Global Molecular Oncology Diagnostics Market
13.7.3 Key Competitors of the Company
13.7.4 Corporate Strategies
13.7.4.1 Synergistic Activities
13.7.5 Business Strategies
13.7.5.1 Product Launch/Approval
13.7.5.2 Expansion
13.7.6 Financials
13.7.7 Analyst Perspective
13.8 Danaher.
13.8.1 Company Overview
13.8.2 Role of Danaher. in the Global Molecular Oncology Diagnostics Market
13.8.3 Key Competitors of the Company
13.8.4 Corporate Strategies
13.8.4.1 Synergistic Activities
13.8.5 Financials
13.8.6 Key Insights about the Financial Health of the Company
13.8.7 Analyst Perspective
13.9 Guardant Health
13.9.1 Company Overview
13.9.2 Role of Guardant Health in the Global Molecular Oncology Diagnostics Market
13.9.3 Key Competitors of the Company
13.9.4 Key Customers of the Company
13.9.5 Corporate Strategies
13.9.5.1 Synergistic Activities
13.9.6 Business Strategies
13.9.6.1 Product Launch/Approval
13.9.7 Financials
13.9.8 Key Insights about the Financial Health of the Company
13.9.9 Analyst Perspective
13.1 HTG Molecular Diagnostics, Inc.
13.10.1 Company Overview
13.10.2 Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Oncology Diagnostics Market
13.10.3 Key Competitors of the Company
13.10.4 Business Strategies
13.10.4.1 Product Launch/Approval
13.10.5 Financials
13.10.6 Key Insights about the Financial Health of the Company
13.10.7 Analyst Perspective
13.11 Illumina, Inc.
13.11.1 Company Overview
13.11.2 Role of Illumina, Inc. in the Global Molecular Oncology Diagnostics Market
13.11.3 Key Competitors of the Company
13.11.4 Corporate Strategies
13.11.4.1 Synergistic Activities
13.11.5 Business Strategies
13.11.5.1 Merger and Acquisition
13.11.6 Financials
13.11.7 Key Insights about the Financial Health of the Company
13.11.8 Analyst Perspective
13.12 Invivoscribe, Inc.
13.12.1 Company Overview
13.12.2 Role of Invivoscribe, Inc. in the Global Molecular Oncology Diagnostics Market
13.12.3 Key Competitors of the Company
13.12.4 Corporate Strategies
13.12.4.1 Synergistic Activities
13.12.5 Business Strategies
13.12.5.1 Product Launch/Approval
13.12.6 Analyst Perspective
13.13 Myriad Genetics, Inc.
13.13.1 Company Overview
13.13.2 Role of Myriad Genetics, Inc. in the Global Molecular Oncology Diagnostics Market
13.13.3 Key Competitors of the Company
13.13.4 Corporate Strategies
13.13.4.1 Synergistic Activities
13.13.5 Business Strategies
13.13.5.1 Product Launch/Approval
13.13.6 Financials
13.13.7 Key Insights about the Financial Health of the Company
13.13.8 Analyst Perspective
13.14 Sysmex Corporation
13.14.1 Company Overview
13.14.2 Role of Sysmex Corporation in the Global Molecular Oncology Diagnostics Market
13.14.3 Key Competitors of the Company
13.14.4 Corporate Strategies
13.14.4.1 Synergistic Activities
13.14.5 Business Strategies
13.14.5.1 Product Launch/Approval
13.14.5.2 Expansion
13.14.6 Financials
13.14.7 Key Insights about the Financial Health of the Company
13.14.8 Analyst Perspective
List of Figures
Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019
Figure 2: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 3: Global Molecular Oncology Diagnostics Market, Dynamics
Figure 4: Share of Key Market Strategies and Developments, January 2019-October 2022
Figure 5: Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 Vs. 2032
Figure 6: Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 Vs. 2032
Figure 7: Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 Vs. 2032
Figure 8: Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 Vs. 2032
Figure 9: Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 Vs. 2032
Figure 10: Global Molecular Diagnostics Market (by Region), $Million, 2021 Vs. 2032
Figure 11: Role of Diagnostics in Healthcare
Figure 12: Global Molecular Oncology Diagnostics Market Segments
Figure 13: Global Molecular Oncology Diagnostics Market: Methodology
Figure 14: Primary Research Methodology
Figure 15: Bottom-Up Approach (Segment-Wise Analysis)
Figure 16: Top-Down Approach (Segment-Wise Analysis)
Figure 17: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 18: Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 19: Hematological Malignancy Prevalence and Incidence Data in North America, 2020
Figure 20: Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 21: Hematological Malignancy Prevalence and Incidence Data in Europe, 2020
Figure 22: Solid Tumor Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 23: Hematological Malignancy Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 24: Global Molecular Oncology Diagnostics Market, $Million, 2019-2021
Figure 25: Prominent FDA-Approved CDx Tests for Molecular Oncology Diagnostics
Figure 26: FDA Guidelines for CDx Approval
Figure 27: Criteria for CMS Coverage/Reimbursement
Figure 28: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 29: Workflow for Medical Device Regulations
Figure 30: Global Molecular Diagnostics Market: Market Dynamics
Figure 31: Likert Scale
Figure 32: Impact Analysis of Market Drivers and Challenges on the Global Molecular Oncology Diagnostics Market
Figure 33: Global Distribution of Cases and Deaths (by Cancer Type), 2020
Figure 34: Global Incidence for Cancer Types (2017-2019)
Figure 35: Product Upgradations and Technological Advancements, 2019-2022
Figure 36: Synergistic Activities, 2019-2021
Figure 37: Share of Key Developments and Strategies, January 2019-October 2022
Figure 38: Share of Mergers and Acquisitions (by Company), January 2019-October 2022
Figure 39: Share of Synergistic Activities (by Company), January 2019-October 2022
Figure 40: Share of Product Launch and Approval Activities (by Company), January 2019-October 2022
Figure 41: Share of Expansion, Insurance, and Other Key Developments (by Company), January 2019-October 2022
Figure 42: Market-Share Analysis for the Global Molecular Oncology Diagnostics Market, $Million, 2021
Figure 43: Growth-Share Analysis of Global Molecular Oncology Diagnostics Market (by Technology), 2021-2032
Figure 44: Global Molecular Oncology Diagnostics Market (by Product)
Figure 45: Share of Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 and 2032
Figure 46: Global Molecular Oncology Diagnostics Market (Kits and Assays), $Million, 2021-2032
Figure 47: Global Molecular Oncology Diagnostics Market (Instruments), $Million, 2021-2032
Figure 48: Global Molecular Oncology Diagnostics Market (Software), $Million, 2021-2032
Figure 49: Global Molecular Oncology Diagnostics Market (by Technology)
Figure 50: Share of Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 and 2032
Figure 51: Global Molecular Oncology Diagnostics Market (Polymerase Chain Reaction), $Million, 2021-2032
Figure 52: Global Molecular Oncology Diagnostics Market (Next-Generation Sequencing), $Million, 2021-2032
Figure 53: Global Molecular Oncology Diagnostics Market (Immunohistochemistry), $Million, 2021-2032
Figure 54: Global Molecular Oncology Diagnostics Market (Fluorescence In-Situ Hybridization), $Million, 2021-2032
Figure 55: Global Molecular Oncology Diagnostics Market (Flow Cytometry), $Million, 2021-2032
Figure 56: Global Molecular Oncology Diagnostics Market (Other Technologies), $Million, 2021-2032
Figure 57: Share of Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 and 2032
Figure 58: Global Molecular Oncology Diagnostics Market (Clinical Diagnostic), $Million, 2021-2032
Figure 59: Global Molecular Oncology Diagnostics Market (Research Use), $Million, 2021-2032
Figure 60: Global Molecular Oncology Diagnostics Market (by Cancer Type)
Figure 61: Share of Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 and 2032
Figure 62: Global Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021 and 2032
Figure 63: Global Molecular Oncology Diagnostics Market (Breast Cancer), $Million, 2021-2032
Figure 64: Global Molecular Oncology Diagnostics Market (Lung Cancer), $Million, 2021-2032
Figure 65: Global Molecular Oncology Diagnostics Market (Colorectal Cancer), $Million, 2021-2032
Figure 66: Global Molecular Oncology Diagnostics Market (Prostate Cancer), $Million, 2021-2032
Figure 67: Global Molecular Oncology Diagnostics Market (Ovarian Cancer), $Million, 2021-2032
Figure 68: Global Molecular Oncology Diagnostics Market (Other Solid Tumors), $Million, 2021-2032
Figure 69: Global Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021 and 2032
Figure 70: Global Molecular Oncology Diagnostics Market (Lymphoma), $Million, 2021-2032
Figure 71: Global Molecular Oncology Diagnostics Market (Leukemia), $Million, 2021-2032
Figure 72: Global Molecular Oncology Diagnostics Market (Multiple Myeloma), $Million, 2021-2032
Figure 73: Global Molecular Oncology Diagnostics Market (Other Hematological Malignancies), $Million, 2021-2032
Figure 74: Share of Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 and 2032
Figure 75: Global Molecular Oncology Diagnostics Market (Hospitals and Diagnostic Centers), $Million, 2021-2032
Figure 76: Global Molecular Oncology Diagnostics Market (Reference Laboratories), $Million, 2021-2032
Figure 77: Global Molecular Oncology Diagnostics Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
Figure 78: Global Molecular Oncology Diagnostics Market (Academic and Research Institutes), $Million, 2021-2032
Figure 79: Global Molecular Oncology Diagnostics Market Snapshot (by Region), $Million, 2021-2032
Figure 80: Global Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
Figure 81: North America Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 82: North America: Market Dynamics
Figure 83: North America Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 84: U.S. Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 85: U.S. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 86: U.S. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 87: U.S. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 88: Canada Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 89: Canada Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 90: Canada Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 91: Canada Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 92: Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 93: Europe: Market Dynamics
Figure 94: Europe Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 95: Germany Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 96: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 97: Germany Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 98: Germany Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 99: France Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 100: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 101: France Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 102: France Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 103: U.K. Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 104: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 105: U.K. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 106: U.K. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 107: Italy Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 108: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 109: Italy Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 110: Italy Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 111: Spain Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 112: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 113: Spain Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 114: Spain Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 115: Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 116: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 117: Rest-of-Europe Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 118: Rest-of-Europe Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 119: Asia-Pacific Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
Figure 120: Asia-Pacific: Market Dynamics
Figure 121: Asia-Pacific Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 122: China Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 123: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 124: China Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 125: China Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 126: India Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 127: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 128: India Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 129: India Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 130: Japan Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 131: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 132: Japan Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 133: Japan Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 134: South Korea Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 135: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 136: South Korea Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 137: South Korea Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 138: Australia Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 139: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 140: Australia Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 141: Australia Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 142: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 143: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 144: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 145: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
Figure 146: Rest-of-the-World Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 147: Total Number of Companies Profiled
Figure 148: Agilent Technologies, Inc.: Product Portfolio
Figure 149: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 150: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 151: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 152: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
Figure 153: Abbott.: Overall Product Portfolio
Figure 154: Abbott.: Overall Financials, $Million, 2019-2021
Figure 155: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 156: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 157: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 158: Biocartis NV.: Product Portfolio
Figure 159: Biocartis NV: Overall Financials, $Million, 2019-2021
Figure 160: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 161: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 162: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 163: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 164: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 165: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 166: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021
Figure 167: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021
Figure 168: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 170: QIAGEN N.V.: Product Portfolio
Figure 171: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 172: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 173: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 174: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 175: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 176: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021
Figure 177: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 178: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 179: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 180: Danaher.: Product Portfolio
Figure 181: Danaher.: Overall Financials, $Million, 2019-2021
Figure 182: Danaher.: Revenue (by Segment), $Million, 2019-2021
Figure 183: Danaher.: Revenue (by Region), $Million, 2019-2021
Figure 184: Danaher.: R&D Expenditure, $Million, 2019-2021
Figure 185: Guardant Health: Overall Product Portfolio
Figure 186: Guardant Health: Overall Financials, $Million, 2019-2021
Figure 187: Guardant Health: Revenue (by Segment), 2019-2021
Figure 188: Guardant Health: R&D Expenditure, $Million, 2019-2021
Figure 189: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 190: HTG Molecular Diagnostics, Inc.: Overall Financials, $Million, 2019-2021
Figure 191: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2019-2021
Figure 192: HTG Molecular Diagnostics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 193: Illumina, Inc.: Overall Product Portfolio
Figure 194: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 195: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 196: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 197: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 198: Invivoscribe, Inc.: Overall Product Portfolio
Figure 199: Myriad Genetics, Inc.: Product Portfolio
Figure 200: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
Figure 201: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 202: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 203: Sysmex Corporation: Overall Product Portfolio
Figure 204: Sysmex Corporation: Overall Financials, $Million, 2019-2021
Figure 205: Sysmex Corporation: Revenue (by Region), $Million, 2019-2021
Figure 206: Sysmex Corporation: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Biomarkers for Different Cancer Types
Table 2: Cost of Liquid Biopsy Based NGS Diagnostic Kits
Table 3: Companies Providing Kits and Assays for Molecular Oncology Diagnostics